Melanoma recurrence patterns after negative sentinel lymphadenectomy

Archives of Surgery

Volumn 140, Issue 9, 2005, Pages 865-872

  Zogakis, Theresa G ^a   Essner, Richard ^a   Wang, He Jing ^a   Turner, Roderick R ^a   Takasumi, Yuki T ^a   Gaffney, Robin L ^a   Lee, Jonathan H ^a   Morton, Donald L ^a   O'Connell, Theodore X ^b   Haigh, Philip I ^b   Greif, Jon M ^b   Difronzo, Andrew L ^b   Wagman, Lawrence D ^b   Wilson, S Eric ^b  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b John Wayne Cancer Institute ^*

Author keywords

[No Author keywords available]

Indexed keywords

EOSIN; HEMATOXYLIN;

ACCURACY; ADULT; AGED; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVIEW; SENTINEL LYMPH NODE; STATISTICAL SIGNIFICANCE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 25144519743     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.140.9.865     Document Type: Review

References (33)

1. Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomized trial: WHO Melanoma Programme. Lancet. 1998;351:793-796.
2. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255-263.
3. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med. 1977;297:627-630.
4. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;61:697-705.
5. Morton DL, Cagle LA, Wong J, et al. Intraoperative lymphatic mapping and selective lymphadenectomy: technical details of a new procedure for clinical stage I melanoma. Paper presented at: Annual Meeting of the Society of Surgical Oncology; May 22, 1990; Washington, DC.
6. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
7. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg. 1999;230:453-463.
8. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976-983.
9. Clary BM, Brady MS, Lewis JJ, Coit DG. Sentinel lymph node biopsy in the management of patient with primary cutaneous melanoma: review of a large singleinstitutional experience with an emphasis on recurrence. Ann Surg. 2001;233: 250-258.
10. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16:2253-2260.
11. Gadd MA, Cosimi AB, Yu J, et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg. 1999;134:381-387.
12. Jansen L, Nieweg OE, Peterse JL, et al. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg. 2000;87:484-489.
13. Chao C, Wong SL, Ross MI, et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg. 2002;184:520-525.
14. Statius Muller MG, van Leeuwen PA, van Diest PJ, et al. Pattern and incidence of first site recurrences following sentinel node procedure in melanoma patients. World J Surg. 2002;26:1405-1411.
15. Wagner JD, Raieri J, Evdokimow DZ, et al. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg. 2003;112:486-497.
16. Fincher TR, McCarty TM, Fisher TL, et al. Patterns of recurrence after sentinel lymph node biopsy for cutaneous melanoma. Am J Surg. 2003;186:675-681.
17. Vuylsteke RJCLM, van Leeuwen PAM, Statius Muller MG, et al. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol. 2003;21:1057-1065.
18. Roberts AA, Cochran AJ. Pathologic analysis of sentinel lymph nodes in melanoma patients: current and future trends. J Surg Oncol. 2004;85:152-161.
19. Cochran AJ, Huang RR, Guo J, Wen DR. Current practice and future directions in pathology and laboratory evaluation of the sentinel node. Ann Surg Oncol. 2001;8:13-17.
20. Bostick P, Essner R, Glass E, et al. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg. 1999;134:43-49.
21. Essner R, Bostick PJ, Glass EC, et al. Standardized probe-directed sentinel node dissection in melanoma. Surgery. 2000;127:26-31.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Thompson JF. The Sydney Melanoma Unit experience of sentinel lymphadenectomy for melanoma. Ann Surg Oncol. 2001;8:44S-47S.
24. Lee JH, Essner R, Torisu-Itakura H, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004;22:3677-3684.
25. Bieligk SC, Ghossein R, Bhattacharya S, Coit DG. Detection of tyrosinase mRNA by reverse transcription polymerase chain reaction in melanoma sentinel nodes. Ann Surg Oncol. 1999;6:232-240.
26. Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA. 1998;280:1410-1415.
27. Goydos JS, Patel KN, Shih WJ, et al. Patterns of recurrence in patients with melanoma and histologically negative but RT-PCR-positive sentinel lymph nodes. J Am Coll Surg. 2003;196:196-204.
28. Kammula US, Ghossein R, Bhattacharya S, Coit DG. Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction-staged sentinel lymph nodes from melanoma patients. J Clin Oncol. 2004;22:3989-3996.
29. Kuo CT, Hoon DS, Takeuchi H, et al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol. 2003;21:3566-3572.
30. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO melanoma program experience. Ann Surg Oncol. 2000; 7:469-474.
31. Statius Muller MG, van Leeuwen PA, de Lange-de Klerk ES, et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma. Cancer. 2001;91:2401-2408.
32. Palmieri G, Strazzullo M, Ascierto PA, et al. Polymerase chain reaction-based detection of circulating melanoma cells as an effective maker of tumor progression. J Clin Oncol. 1999;17:304-311.
33. Ghossein RA, Coit D, Brennan M, et al. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin Cancer Res. 1998;4:419-428.